JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
EVRY, France, June 27, 2016 -- Global Bioenergies (Alternext Paris: ALGBE) announces having delivered isobutene produced at its industrial pilot to Clariant, a leading specialty chemical company.
Clariant is a Swiss stock-market listed company with revenues exceeding 5 billion euros in 2015, active in a variety of chemical markets such as specialty polymers.
Global Bioenergies' most advanced program consists in the production of high-purity isobutene from renewable resources. A sample of such renewable isobutene, produced at the company's industrial pilot plant, has been shipped to Clariant, where tests regarding Clariant's application of interest have been carried out successfully.
Thomas Buhl, Head of Business Development at Global Bioenergies comments: "After Cristal Union, Audi, Arkema, CFBP, Arlanxeo and L'Oréal, we are pleased to add a seventh company to our list of major industrialists interested in our technology. Clariant is known for developing innovative solutions towards a more environment-friendly chemistry, a mission shared by Global Bioenergies."
About GLOBAL BIOENERGIES
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performances of its process, operates its industrial pilot, builds its demo plant in Germany, and prepares the first full-scale plant through a Joint-Venture with Cristal Union, named
IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 - ALGBE).
Should you like to be kept informed, subscribe to our news feed on
www.global-bioenergies.com
Follow us on Twitter: @GlobalBioenergi
Contact
GLOBAL BIOENERGIES
Thomas BUHL
Head of Business Development
Phone: +33 (0)1 64 98 20 50
Email: [email protected]
Press release http://hugin.info/166909/R/2023313/751756.pdf
HUG#2023313
